Evidence map›Paper›PMID 37328838›Full record

ArticleMolecular cancer2023

Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.

Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez and 12 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 5 countries.

Rodrigo Entrialgo-CadiernoProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Cristina Cueto-UreñaProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Connor WelchProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Iker FeliuProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Irati MacayaProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Laura VeraProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Xabier MoralesImaging Unit and Cancer Imaging Laboratory, University of Navarra, CIMA, Pamplona, Spain.
Sandra Vietti MichelinaDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy.
Pietro ScaparoneDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy.
Ines LopezProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Elodie DarboUniversity of Bordeaux, INSERM, BRIC, Bordeaux, 1312, F‑33000, France.
Oihane EriceProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Adrian VallejoProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Haritz MorenoProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Ainhoa Goñi-SalaverriMolecular Therapies Program, University of Navarra, CIMA, Pamplona, Spain.
David Lara-AstiasoMolecular Therapies Program, University of Navarra, CIMA, Pamplona, Spain.
Nils HalbergDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Ivan Cortes-DominguezImaging Unit and Cancer Imaging Laboratory, University of Navarra, CIMA, Pamplona, Spain.
Elizabeth GuruceagaBioinformatics Platform, University of Navarra, CIMA, Pamplona, Spain.
Chiara AmbrogioDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy.
Fernando LecandaProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain.
Silve VicentProgram in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, Pamplona, 31008, Spain. silvevicent@unav.es.
Universidad de Navarra · ESUniversity of Turin · ITNavarre Institute of Health Research · ESCentro de Investigación Biomédica en Red de Cáncer · ESInserm · FRUniversity of Bergen · NOWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37328838
PMCPMC10273529
OpenAlexW4380987761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.